Диссертация (1139774), страница 23
Текст из файла (страница 23)
- V.176. - P. 405-6.67.Barnes T.R., Paton C. Antipsychotic polypharmacy in schizophrenia: benefits andrisks // CNS Drugs. - 2011. - V. 25(5). - P. 383-99.68.Baxter K. Stockley’s Drug Interactions, 9th edn. London, UK: PharmaceuticalPress, 2010. - 1700 p.69.Bebbington P.E., Angermeyer M., Azorin J.M., Marwaha S., Marteau F., ToumiM. Side-effects of antipsychotic medication and health-related quality of life inschizophrenia // Acta Psychiatrica Scandinavica. Supplementum. -2009.
-V. 438. - P.22-8.70.Berecz R., Dorado P., De La Rubia A., Cáceres M.C., Degrell I., LLerena A. Therole of cytochrome P450 enzymes in the metabolism of risperidone and its clinicalrelevance for drug interactions // Current Drug Targets. - 2004. - V. 5 (6). - Р. 573-79.71.Black D.W., Fisher R. Mortality in DSM-III-R schizophrenia // SchizophreniaResearch. - 1992. - V. 7. - P. 109-16.72.Bleakley S.
Identifying and reducing the risk of antipsychotic drug interactions //Progress in Neurology and Psychiatry. - 2012. - V.16. - P. 20-24.73.Bobier C., Warwick M. Factors associated with readmission to adolescentpsychiatric care // Australian and New Zealand Journal of Psychiatry. - 2005. - V. 39(7).- P. 600-6.74.Bogni A., Monshouwer M., Moscone A. Substrate specific metabolism bypolymorphic cytochrome P450 2D6 alleles // Toxicology in Vitro.
- 2005. - V. 19. - P.621-29.75.Boulton D.W., Devane C.L., Liston H.L., Markowitz J.S. In vitro P-glycoproteinaffinity for atypical and conventional antipsychotics // Life Sciences. - 2002. - V. 71. P. 163-9.76.Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians,Africans and their descendants // Pharmacogenomics.
- 2002. - V. 3(2). - P. 229-43.14177.Brockmoller J., Kirchheiner J., Schmider J., Walter S., Sachse C., Müller-Oerlinghausen B., Roots I. The impact of the CYP2D6 polymorphism on haloperidolpharmacokinetics and on the outcome of haloperidol treatment // Clinical Pharmacology& Therapeutics. - 2002. - V. 72. - P. 438-52.78.Brøsen K., Gram L.F. Clinical significance of the sparteine/debrisoquineoxidation polymorphism // European Journal of Clinical Pharmacology.
- 1989. - V.36(6). - P. 537-47.79.Buckley P.F. Factors that influence treatment success in schizophrenia // TheJournal of Clinical Psychiatry. - 2008. - №69 (Suppl 3). - P. 4-10.80.Carnahan R. No difference in extrapyramidal side effects between first-generationand second-generation antipsychotics // Evidence-Based Mental Health. - 2012. - V.15(4). - P. 91.81.Carnahan R.M., Lund B.C., Perry P.J., Chrischilles E.A.
Increased risk ofextrapyramidal side effect treatment associated with atypical antipsychotic polytherapy// Acta Psychiatrica Scandinavica. - 2006. - V. 113. – P. 135-141.82.Casey D.E. Tardive dyskinesia and atypical antipsychotic drugs // SchizophreniaResearch. - 1999. - V. 35. - P. 61-66.83.Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P., Baldessarini R.J.Multiple vs.
single antipsychotic agents for hospitalized psychiatric patients: Casecontrol study of risks versus benefits // American Journal of Psychiatry. - 2004. - V.161(4). - P. 700-6.84.Changasi A.H., Shams T.A., Pouget J.G., Müller D.J. Genetics of antipsychoticdrug outcome and implications for the clinician: into the limelight // Translationaldevelopmental psychiatry. - 2014.
V. 2(1):24663.85.Chaumartin N., Monville M., Lachaux B. Dysphagia or dysphagias duringneuroleptic medication? // Encephale. - 2012. - V. 38(4). - P. 351-5.86.Cheng F., Jones P.B. Second-generation atypical versus first-generationconventional antipsychotic drug treatment in schizophrenia: another triumph of hopeover experience? // Therapeutic Strategies in Schizophrenia (eds Mortimer A.,McKenna P.J.): Clinical Publishing, 2010. - P.
193–206.14287.Chou W.H., Yan F.X., de Leon J., Barnhill J., Rogers T., Cronin M., Pho M.,Xiao V., Ryder T.B., Liu W.W., Teiling C., Wedlund P.J. Extension of a pilot study:impact from the cytochrome P450 2D6 polymorphism on outcome and costs associatedwith severe mental illness // Journal of Clinical Psychopharmacology. - 2000. - V. 20. P.
246-51.88.Chowdhury N.I., Remington G., Kennedy J.L. Genetics of antipsychotic-inducedside effects and agranulocytosis // Current Psychiatry Reports. - 2011. - V. 13(2). - P.156-65.89.Classen D.C., Resar R., Griffin F., Federico F., Frankel T., Kimmel N.,Whittington J.C., Frankel A., Seger A., James B.C. Global trigger tool shows thatadverse events in hospitals may be ten times greater than previously measured // HealthAffairs (Millwood). - 2011. - V. 30(4). - P. 581-9.90.Codeine sulfate - codeine sulfate tablet.
West-Ward Pharmaceuticals Corp. URL:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa3ed180-298a-4f9d-9d0515182d7218bf&audience=professional. (дата обращения 07.02.2017).91.Committee for proprietary medicinal products opinion following an article 36referral:sertindole.EuropeanMedicinesAgency,2002.URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Sertindole/human_referral_000111.jsp. (дата обращения 15.02.2016).92.Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychoticpolypharmacy increase the risk for metabolic syndrome? // Schizophrenia Research. 2007. - V. 89(1-3). - P.
91-100.93.Crescenti A., Mas S., Gassó P., Parellada E., Bernardo M., Lafuente A.Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidalside-effects in patients receiving antipsychotic therapy // Clinical and ExperimentalPharmacology and Physiology. - 2008. - V. 35(7). - P. 807-11.94.Dahl M.L. Cytochrome P450 phenotyping/genotyping in patients receivingantipsychotics: useful aid to prescribing? // Clinical Pharmacokinetics.
- 2002. - V. 41. P. 453-70.14395.De Hert M., Hanssens L., Wampers M., Van Winkel R., Van Eyck D., Scheen A.Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospectivestudy of patients treated with second-generation antipsychotics // SchizophreniaBulletin. - 2007. - V. 33.
- P 560.96.Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC)transporter superfamily // Genome Research. - 2001. - V. 11(7). - P. 1156-66.97.Dieperink M., Drogemuller L. Industry-sponsored grand rounds and prescribingbehavior // Journal of the American Medical Association. - 2001. - V. 285. - P.1443-44.98.DilokthornsakulP., Thoopputra T., PatanaprateepO., Kongsakon R.,Chaiyakunapruk N. Effects of medication adherence on hospitalizations and healthcarecosts in patients with schizophrenia in Thailand // SAGE Open Medicine.
- 2016. - V. 4:2050312116637026.99.DPWGGuidelineforhaloperidolandCYP2D6.–URL:https://www.pharmgkb.org/chemical/PA449841 (дата обращения 07.02.2017).100. Dziewas R., Warnecke T., Schnabel M., Ritter M., Nabavi D.G., Schilling M.,Ringelstein E.B., Reker T. Neuroleptic-induced dysphagia: case report and literaturereview // Dysphagia. - 2007. - V. 22. – P.
63-7.101. Eberhard J., Lindström E., Levander S. Tardive dyskinesia and antipsychotics: a5-year longitudinal study of frequency, correlates and course // International ClinicalPsychopharmacology. - 2006. - V. 21(1). - P. 35-42.102. El-Gaaly S., St John P., Dunsmore S., Bolton J.M.
Atypical neuroleptic malignantsyndrome with quetiapine: a case report and review of the literature // Journal ofClinical Psychopharmacology. - 2009. - V. 29(5). - P. 497-9.103. Ely S.F., Neitzel A.R., Gill J.R. Fatal diabetic ketoacidosis and antipsychoticmedication // Journal of Forensic Sciences. - 2013. - V. 58(2). - P. 398-403.104. Fernández-Santander A., Santiago C., Díez-Durán S., González M., de Castro E.,Guijarro J., Bandrés F., Lucia A., Gómez-Gallego F.
Identification of CYP2D6 nullvariants among long-stay, chronic psychiatric inpatients: is it strictly necessary? //Human Psychopharmacology. - 2008. - V. 23(6). - P. 533-6.144105. Ferner R.E., Aronson J.K. Preventability of drug-related harms - part I: Asystematic review // Drug Safety. - 2010. - V. 33(11). - P. 985-94.106. Figueroa R., Harman J., Engberg J. Use of claims data to examine the impact oflength of inpatient psychiatric stay on readmission rate // Psychiatric Service. - 2004. V. 55(5). - P.
560-5.107. Fisher M.D., Reilly K., Isenberg K., Villa K.F. Antipsychotic patterns of use inpatients with schizophrenia: polypharmacy versus monotherapy // BMC Psychiatry. 2014. - V. 14. - P. 341.108. Fleeman N., McLeod C., Bagust A., Beale S., Boland A., Dundar Y., JorgensenA., Payne K., Pirmohamed M., Pushpakom S., Walley T., de Warren-Penny P., DicksonR. The clinical and cost effectiveness of testing for cytochrome P450 polymorphisms inpatients treated with antipsychotics: a systematic review and economic evaluation //Health Technology Assessment.
- 2010. - V. 14(3). - P. 1-157.109. Fleischhacker W.W., Roth S.D., Kane J.M. The pharmacologic treatment ofneuroleptic induced akathisia // Journal of Clinical Psychopharmacology. - 1990. - V.10. - P. 12-21.110. Fontanella C.A., Campo J.V., Phillips G.S., Hiance-Steelesmith D.L., SweeneyH.A., Tam K., Lehrer D., Klein R., Hurst M. Benzodiazepine use and risk of mortalityamong patients with schizophrenia: a retrospective longitudinal study // Journal ofClinical Psychiatry.
- 2016. - V. 77(5). - P. 661-7.111. Fox C., Richardson K., Maidment I.D., Savva G.M., Matthews F.E., Smithard D.,Coulton S., Katona C., Boustani M.A., Brayne C. Anticholinergic Medication Use andCognitive Impairment in the Older Population // The Medical Research CouncilCognitive Function and Ageing Study Journal of the American Geriatrics Society.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
